Sildenafil / Testosterone Troche

Overview of Sildenafil / Testosterone Troche

Dosage Strength

100/100 mg

General Information

Sildenafil
Originally intended to treat pulmonary hypertension, angina, and other cardiovascular diseases, sildenafil citrate was unintentionally discovered to be useful in males suffering from erectile dysfunction (ED). Prior to the discovery of its therapeutic effects in the treatment of ED, this condition was thought to be an unavoidable component of aging in men or the result of underlying psychological problems. After being approved by the U.S. Food and Drug Administration in 1998 for the treatment of ED, sildenafil citrate’s popularity has skyrocketed over the last few decades, with health care providers generally recommending this medication as first-line therapy in the management of erectile dysfunction in men. Other aspects that contribute to its attraction and popularity include the fact that sildenafil citrate can be taken orally on demand and is generally well tolerated with little side effects. 1

Sildenafil citrate is a vasoactive medicine that belongs to the pharmacologic class of PDE-5 inhibitors; it is a competitive antagonist of this enzyme. PDE-5 is distributed throughout the human body, particularly in the corpus cavernosum within the penis, striated and smooth muscle, and platelets. However, PDE-5 is more prevalent in the penile corpus cavernosum, which explains why sildenafil citrate can function selectively in this area of the body. 2

Sildenafil citrate is often used orally. It can, however, be given intravenously or sublingually. Although its most common therapeutic application is for the treatment of erectile dysfunction, it is also used to treat pulmonary hypertension, infant pulmonary hypertension, Raynaud’s phenomenon refractory to other vasodilators, and to prevent pulmonary edema at high altitudes. Following oral administration, sildenafil citrate is rapidly absorbed, primarily in the small intestine, and is then carried through the bloodstream to its site of action. The hepatic isoenzymes cytochrome P450 3A4 and cytochrome P450 2C9 metabolize sildenafil citrate in the liver. Following hepatic metabolism, metabolites are primarily eliminated in the stool and, to a lesser extent, in the urine. 234

The Food and Medication Administration classifies sildenafil citrate as a pregnancy category B drug. Studies have found no definitive dangers to fetuses when sildenafil is given to pregnant women. There are currently no proven clinical indications for the use of sildenafil citrate in women. To yet, no studies have shown that sildenafil citrate has the same benefits in women as it does in men. Other trials, however, are still continuing, and the results may provide additional insight into the usability and benefits of sildenafil in women.

Testosterone
The predominant androgen present in the body is testosterone. Cells in the testis, ovary, and adrenal cortex produce endogenous testosterone. In the treatment of hypogonadism, either congenital or acquired, testosterone is employed. Testosterone is also the most effective exogenous androgen for the palliative treatment of postmenopausal women with breast cancer. Testosterone was first used in 1938, and the FDA approved it in 1939. Anabolic steroids, which are testosterone derivatives, have been used illegally and are now restricted substances. In 1991, testosterone, like many anabolic steroids, was designated as a restricted substance. Uniumed Pharmaceuticals developed testosterone cream as AndroGel in the United States, and it was FDA approved in 2000 for the treatment of testosterone deficiency, which often results in a variety of hypogonadic conditions ranging from mood and energy to sexual dysfunctions, as well as a treatment for several injury-related conditions such as those experienced by severe burn and accident victims. AndroGel is a very popular form of testosterone that is sold around the world under a few less well-known brand/trade names, most notably Testogel (manufactured in the UK by Laboratoires Besins and distributed by Bayer), Testim (manufactured in the US by Auxilium Pharmaceuticals, Inc.), and various generic versions often sold under the name testosterone cream or gel.

The transdermal testosterone cream delivery technique targets the same, or very comparable, body locations as injections and other kinds of testosterone. More specifically, maximum absorption of testosterone cream is attained when it is applied to heavily muscled bodily regions (as with injectable testosterone). Because more muscle at the area of application correlates to a greater number of testosterone-absorbing capillaries, testosterone may be shuttled into the bloodstream more quickly. 5

References

1.Goldstein, I., Burnett, A., Rosen, R.C., Park, P.W., Stecher, V.J.,” The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction”, Sexual Medicine Reviews, vol.7 issue 1, pp. 115-128. 2019. Available: https://www.sciencedirect.com/science/article/pii/S2050052118300830?via%3Dihub
2.McCullough, A.R., “Four-Year Review of Sildenafil Citrate”, Reviews in Urology, vol.4 supp 3, S26 – S38. 2002. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476025/
3.”Sildenafil citrate”, Prescribers Digital Reference. Available: https://www.pdr.net/drug-summary/Viagra-sildenafil-citrate-471
4.”Sildenafil”, Drug Bank. Available: https://go.drugbank.com/drugs/DB00203
5.Dastjerdi, M.V., Hosseini, S., Bayani, L., “Sildenafil citrate and uteroplacental perfusion in fetal growth restriction”, Journal of Research in Medical Sciences, vol.17 issue 7, pp.632-636. 2012. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685778/
7.Umrani, D.N., Goyal, R.K., “Pharmacology of Sildenafil Citrate”, Indian Journal of Physiology and Pharmacology, vol.43 issue 2, pp. 160-164. 1999. Available: https://www.ijpp.com/IJPP%20archives/1999_43_2/160-164.pdf
8.Cheitlin, M.D., Hutter, A. M., Brindis, R.G., Ganz,P., Kaul,S., Russell, R.O., Zusman, R. M., Forrester, J.S., Douglas, P.S., Faxon, D.P., Fisher, J.D., Gibbons, R.J., Halperin, J.L., Hochman, J.S., Kaul, S., Weintraub, W.S., Winters, W.L., Wolk, M.J.,” Use of Sildenafil (Viagra) in Patients With Cardiovascular Disease”, Circulation, vol.99 issue 1. 1999. Available: https://www.ahajournals.org/doi/10.1161/01.CIR.99.1.168
9.Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 2005;280:19496-506.
10.Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2014 Jun.
11.Barnes KM, Dickstein B, Cutler GB Jr, et al. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996;35:4820-7.
12.Smith, B.P., Babos, M., “Sildenafil”, StatPearls. 2020. Available: https://www.ncbi.nlm.nih.gov/books/NBK558978/
13.DELATESTRYL (Testosterone Enanthate Injection, USP) package insert. Lexington, MA: Indevus Pharmaceuticals, Inc.; 2007 July.
14.Axiron (testosterone) topical solution, package insert. Indianapolis, IN: Lilly USA, LLC; 2011 Dec.
15.The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
16.Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
17.WD Finkle, S Greenland, GK Ridgeway, et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. DOI: 10.1371/journal.pone.0085805
18.FDA Medwatch – FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Retrieved January 31, 2014. Available on the World Wide Web http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm
19.Natesto (testosterone) nasal gel package insert. Durants, Christ Church Barbados: Trimel BioPharma SRL; 2014 May.
20.(testosterone gel) package insert. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2010 Apr.
21.Androgel (testosterone gel) package insert. Marietta, GA: Solvay Pharmaceuticals, Inc.; 2012 Sept.
22.Striant (testosterone buccal system) package insert. Livingston, NJ: Columbia Laboratories, Inc.; 2014 Mar.
23.Fortesta (testosterone) gel, package insert. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010 Dec.
24.Aveed (testosterone undecanoate Injection) package insert. Malvern, PA: Endo Pharmaceuticals Solutions Inc.; 2014 Mar.
25.DEPO-TESTOSTERONE (testosterone cypionate) injection, package insert. New York, NY: Pharmacia & Upjohn Co.; 2006 Sept.
26.Kochenour NK. Lactation suppression. Clin Obstet Gynecol. 1980;23:1045-1059.
27.Testim (testosterone gel) package insert. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2010 Apr.
28.Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 2005;280:19496—506.
29.Barnes KM, Dickstein B, Cutler GB Jr, et al. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996;35:4820—7.
30.Wells PS, Holbrook AM, Crowther NR et al. Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676—83.
31.Goffin E, Pirson Y, Geubel A, et al. Cyclosporine-methyltestosterone interaction. Nephron 1991;59:174—5.
32.Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, et al. Possible cyclosporin-danazol interaction in a patient with aplastic anaemia. Am J Hematol 1999;62:63—4.
33.Moller BB, Ekelund B. Toxicity of cyclosporine during treatment with androgens. N Engl J Med 1985;313:1416.
34.Ross WB, Roberts D, Griffin PJ, et al. Cyclosporin interaction with danazol and norethisterone. Lancet 1986;1:330.
35.Androgel® (testosterone gel) package insert. Montrogue, France: Laboratories Besins International; 2005 Aug.
36.Zoladex® (goserelin acetate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2003 Dec.
37.Viadur® (leuprolide implant) package insert. Westhaven, CT: Bayer Pharmaceuticals; 2002 May.
38.Humatrope™ (somatropin);package insert. Indianapolis, IN: Eli Lilly and Company; 2003 Jul.
39.Androderm® (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 1999 Jan.
40.Propecia® (finasteride) package insert. Whitehouse Station, NJ: Merck & Co., INC.; 2003 Oct.
41.Avodart™ (dutasteride) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005 May.
42.Robbers JE, Tyler VE. Tyler’s Herbs of Choice: the Therapeutic Use of Phytomedicinals. Binghamton NY: Haworth Herbal Press, Inc.; 1999.
43.German Commission E. Saw Palmetto berry, Sabal fructus, monograph Published March 2, 1989 and revised January 17, 1991. In: Blumenthal, M et al ., eds. The complete German Commission E Monographs -Therapeutic Guide to Alternative Medicines. Bosto
44.Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12:S327—33.
45.Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
46.Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male 2003;6:1—7.
47.Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity, and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Clin Endocrinol 2006; 154:899—90
48.Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab 1996; 81:1582—5.
49.Corrales JJ, Burgo RM, Garcia-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53:666—72
50.Lee CH, Kuo SW, Hung YJ, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Res 2005;31:139—148.
51.Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987;64:960—3.
52.Aldercreutz H, Mazur W. Phyto-estrogens and western diseases. Annals of Medicine 1997;29:95—120.
53.Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2013 Dec.
54.Letairis™ (ambrisentan) package insert. Foster City, CA: Gilead Sciences, Inc; 2008 Oct.
55.Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015 Jan.
56.Gilotrif (afatinib) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2013 Nov.

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.

Schedule Your Free Consultation